In the rapidly evolving field of regenerative medicine, REPROCELL’s StemRNATM Clinical iPSCs provide a benchmark for clinical grade induced pluripotent stem cells (iPSCs). These high-quality iPSCs provide a foundation for various cell therapy programs, ensuring safety, consistency, and regulatory compliance. Our clinical iPSCs are currently being evaluated by many biopharma companies globally, are selected for regulatory filings and are IND approved. REPROCELL is a trusted partner for cell therapy developers who are seeking robust, high-quality clinical iPSC banks that meet industry standards.
StemRNA™ Clinical iPSCs: The Gold Standard for Clinical Applications
REPROCELL’s StemRNATM Clinical iPSCs are generated utilizing an in-house developed proprietary, footprint-free RNA reprogramming technology, eliminating genomic integration, and drastically enhancing the safety profile for clinical applications.
To meet the highest global standards, the donor material and the resulting clinical iPSCs undergo rigorous quality control to ensure compliance with the FDA, EMA and PMDA. These processes include extensive informed consent and donor screening under IRB-approved ethical guidelines to ensure donor eligibility. Additionally, the usage of media and reagents, process controls, and cell bank characterization comply with set guidelines, all monitored through Good Documentation Practices.
Seamless Integration into GMP Manufacturing Pipelines
A key advantage of REPROCELL’s iPSC technology is its seamless transition from research to clinical-grade production. StemRNATM Clinical iPSCs (Seed Clones) serve as the foundation for GMP Master and Working Cell Banks, essential for large-scale cell therapy manufacturing. For a more cost-effective approach, we provide research versions (Pilot Clones) of our clinical lines to enable process development and optimization. Researchers can choose from existing banked lines or request custom iPSC lines tailored to their therapeutic needs.
REPROCELL also offers comprehensive regulatory support, ensuring piece of mind for filings with regulatory authorities. Additionally, we offer a simple one-time license fee structure for therapeutic use with no further maintenance fees or percentage royalties downstream.
Broad Therapeutic Potential: From Neurology to Immunotherapy
REPROCELL’s clinical iPSCs demonstrate true pluripotency, and they have been successfully differentiated into various cell types across multiple therapeutic areas, including:
- Functional liver spheres
- CD34-derived NK cells
- Cortical & dopaminergic neurons and astrocytes
- Cardiomyocytes and human ventricular cardiac tissues
- iPSC-derived MSCs
Gameto: A Testament to REPROCELL’s Quality and Reliability
REPROCELL’s clinical iPSCs played a crucial role in Gameto Inc.’s groundbreaking in vitro oocyte maturation technology, Fertilo, which recently received FDA Investigational New Drug (IND) clearance and approval for Phase III clinical trials in the US.
Fertilo utilizes ovarian support cells derived from REPROCELL’s StemRNATM Clinical iPSCs to recapitulate the ovarian microenvironment ex vivo.
As the first iPSC-based therapy to reach Phase 3 clinical trials in the U.S., Fertilo highlights the strength of REPROCELL’s iPSC technology and its groundbreaking clinical potential. This milestone marks the first use of REPROCELL’s Clinical iPSCs in a U.S. Phase 3 clinical trial, underscoring their transformative impact on regenerative medicine.
Shaping the Future of iPSC-Based Medicine
REPROCELL remains committed to providing high-quality, regulatory-compliant iPSCs that drive therapeutic innovation to support the next generation of iPSC-based therapies.
To discover how REPROCELL’s StemRNATM Clinical iPSCs can advance your clinical pipeline, visit our website: GMP iPSC Production Service.